π Lecture 31 β Basic Neurochemistry
π Overview: This lecture explores the foundational principles of neurochemistry, detailing the step-by-step process of synaptic transmission, from synthesis to recycling of neurotransmitters. It also classifies the major neurotransmitters and explains their roles in behavior modulation, along with methods used to locate and study these neurochemicals in the brain. This knowledge is crucial for understanding how drugs affect behavior and how neurological aberrations arise.
ποΈ Topics Covered
The lecture covers the six major steps of synaptic transmission: synthesis, release, generation of postsynaptic potential, action in the postsynaptic membrane, inactivation, and vesicular membrane recycling. It then details the methods for locating neurotransmitters, including histofluorescence, receptor binding autoradiography, monoclonal antibodies, and microiontophoresis. Finally, it classifies the six major groups of neurotransmitters: amino acids, monoamines (catecholamines and indoleamine), soluble gases, acetylcholine, and neuropeptides.
π Lecture Summary
Neurotransmitters: synaptic transmission
Synaptic transmission is divided into several clear-cut, sequential steps, each dependent on the previous one.
1. Synthesis of the NT and storage in the synaptic vesicles
Synaptic vesicles are storage containers that protect neurotransmitters from deactivating enzymes. They are manufactured from proteins by the Golgi apparatus in the cell body and travel down the axon to the synaptic buttons via the axonal transport system. For Neuropeptides (short chains of amino acids), packaging occurs in the cisternae within the synaptic buttons. For non-peptide neurotransmitters, packaging into vesicles occurs within the cytoplasm before transport. The axonal transport system has two directions:
- Anterograde (forward) axonal transport moves materials from the cell body to the synaptic ending through microtubules. The fast anterograde transport moves synaptic vesicles at a speed of 400 millimeters per day.
- Slow anterograde transport is used when materials and vesicles ooze along the axon at a speed of less than 10 millimeters per day.
2. Release of the Neurotransmitter
When an action potential reaches the presynaptic ending, it triggers the opening of calcium-gated channels. Calcium entering the terminal button triggers the release of the neurotransmitter through a process called exocytosis. This involves: a) Vesicles moving to the terminal membrane. b) Vesicles fusing with the presynaptic membrane to release neurotransmitter molecules into the synaptic cleft. c) The vesicle membrane merging with the presynaptic membrane, which then mends.
3. Generation of the post synaptic potential
This describes the action at the receiving end after the neurotransmitter molecule crosses the synaptic cleft and binds to the postsynaptic membrane.
a) Binding of NT molecules to post receptor site: Molecules must chemically "bind" to a specific receptor protein on the membrane. Only molecules with the correct shape and chemical composition can bind, opening gates for specific molecules.
b) Changes in ionic gates: The binding leads to changes in chemically-gated ion channels via two methods: i) Direct method: Binding directly opens or closes the channels. ii) Indirect method: A series of chemical changes occur through a 2nd messenger, specifically Cyclic Adenosine Monophosphate (CAMP). CAMP is involved in converting ATP (Adenosine triphosphate) to cAMP, which is needed for cellular energy.
4. Action in the Post Receptor membrane
Two kinds of actions can occur in the postsynaptic membrane:
- Excitatory Postsynaptic Potential (EPSP): Generates an action potential in the postsynaptic membrane.
- Inhibitory Postsynaptic Potential (IPSP): Inhibits ongoing activity in the cell membrane.
These actions depend on the type of neurotransmitter involved and the site of action. A neurotransmitter may be excitatory at one site and inhibitory at another.
5. Inactivation of the NT
Neurotransmitters must be removed from the cleft to maintain system efficiency. Two main processes deactivate them:
- Reuptake: The neurotransmitter returns to the presynaptic area to be reabsorbed, repackaged into vesicles, and reused.
- Deactivating: Specialized enzymes locate and degrade free-floating neurotransmitter molecules in the synaptic cleft.
π‘ Why this matters: Without these deactivation processes, a single dose of a stimulant could have a lifelong effect, and the synaptic cleft would become cluttered with molecules.
6. Recycling of the vesicular membrane
Vesicles that ruptured during exocytosis are recycled. Excess membrane pieces are broken off and returned to the cytoplasm. They can then be: a) Filled with non-peptide NT by the cisternae. b) Sent back to the cell body by retrograde transport (traveling at 200 millimeters per day). c) Refilled with NT by the Golgi bodies in the cell soma. d) Broken down and their molecules recycled.
Methods of Locating NT
Several techniques are used for localizing neurotransmitters and their projections:
-
Histofluoresence Technique: Developed by Falck and Hillarp in the early 1960s. When monoamine neurotransmitters are exposed to formalin fixative, they glow under a fluorescent light. This technique is useful for locating monoamines but cannot differentiate between different types within the class.
-
Receptor Binding Autoradiography: Neurotransmitters are radiolabeled with a radioactive isotope (e.g., Hydrogen-3 or Carbon-3). The labeled ligand (molecule that binds to a target) is then exposed to neural tissue. The tissue is placed on a photographic plate, where high radioactivity areas show up.
-
Monoclonal Antibodies: This uses immunocytochemistry procedures. Specific monoclonal antibodies are developed to target particular proteins (all NTs are chains of amino acids) and are injected to identify specific regions and target proteins.
-
Microiontophoresis (push pull cannulae): This procedure analyzes chemicals released within the synapse. A double-barreled pipette monitors the response of postsynaptic sites. A weak current stimulates the neuronal ending, causing a discharge that is pulled out for analysis and checked for EPSPs or IPSPs on an oscilloscope.
Major Neurotransmitters
There are six major groups of neurochemicals classified as neurotransmitters:
-
Amino acids: Formed from chains of amino acids. This large group includes Glutamate (excitatory), GABA (Gamma-Aminobutyric Acid) (inhibitory), Glycine, and Aspartate. These have relatively quick-acting synaptic connections.
-
Monoamines I: Catecholamines: Synthesized from a single amino acid and have one catechol group. Neurons have bulbous, bead-like knobs. The major catecholamines are: Dopamine, Norepinephrine (also known as Noradrenaline), and Epinephrine (also known as Adrenaline).
-
Monoamines II: Indoleamine: Also a monoamine but with a different structure (indoleacetic acid). The major indoleamine is Serotonin.
-
Soluble gases: Small molecule neurotransmitters that are lipid-soluble and diffuse through cell membranes. They work through 2nd messengers and break down immediately. Nitric oxide and carbon monoxide are two examples.
-
Acetylcholine: A small molecule transmitter that is unique; there are no other NTs in this group. It is the only NT that works on neuromuscular joints.
-
Neuropeptides: A large number of peptides that are possible NT candidates. Well-known examples include the brain opioids, Endorphins (large molecules), Enkephalins (small molecules), pituitary peptides, and Substance P.
π Definition β Exocytosis: The process by which a vesicle's contents are released into the synaptic cleft by the fusion of the vesicle membrane with the presynaptic membrane. π Definition β Second Messenger: A molecule (like CAMP) that intervenes in a signal from a neurotransmitter binding to a receptor, translating the message for further action inside the cell. π Definition β Reuptake: The process by which a neurotransmitter is taken back into the presynaptic neuron for recycling. π Formula: Fast Anterograde Transport Speed = 400 mm/day β The very fast speed at which synaptic vesicles are transported from the cell body to the synaptic ending. π Example: Receptor Binding Autoradiography: A neurotransmitter like dopamine is radiolabeled. This labeled molecule is injected into a brain area. The animal is then killed, and the brain is sliced and exposed to a photographic plate. Dark spots on the plate indicate where the radioactive dopamine bound to its receptors.
β Key Takeaways
Students must remember the six sequential steps of synaptic transmission, as this process is fundamental to all neural communication. The critical role of calcium in triggering exocytosis, and the distinct functions of the direct and indirect methods of ion channel opening, are essential. The difference between EPSP and IPSP is a core concept for understanding neural excitation and inhibition. Finally, knowing the six major neurotransmitter groups (Amino acids, Catecholamines, Indoleamines, Soluble gases, Acetylcholine, and Neuropeptides) and the function of key examples like Glutamate, GABA, and Dopamine is crucial for understanding behavior and the action of drugs.
π§ Quick Revision Questions
- What are the two directions of axonal transport, and what are their respective speeds?
- Name the ion whose influx triggers the release of neurotransmitters via exocytosis.
- What are the two main processes by which a neurotransmitter is inactivated in the synaptic cleft?
- What does EPSP stand for, and what effect does it have on the postsynaptic neuron?
- List the six major groups of neurotransmitters mentioned in the lecture.
π Lecture 32 β Basic Neurochemistry
π Overview: This lecture covers the fundamental principles of neurochemistry with a primary focus on dopamine as a major catecholaminergic neurotransmitter. It explains the synthesis pathway of dopamine, its three major neural pathways in the brain, and how pharmacological agents can modify dopamine function at each step of synthesis and transmission. The lecture also explores dopamine's critical role in modulating key behaviors including motor activity, depression, hyperactivity, and schizophrenia.
ποΈ Topics Covered
The lecture begins with an introduction to major neurotransmitters and classification systems including monoamines (catecholamines and indoleamines), acetylcholine, amino acids, and peptides. It then provides an in-depth examination of dopamine, covering its discovery, synthesis pathway from tyrosine, the D1 and D2 receptor types, and the three major dopaminergic pathways (nigrostriatal, mesolimbic, and tuberoinfundibular). The mechanisms of synaptic transmission and drug action are detailed, including the specific steps where agonists and antagonists can interact. The lecture concludes with a comprehensive analysis of dopamine's behavioral correlates, examining its involvement in motor activities, Parkinson's disease, depression, hyperactivity, and schizophrenia.
π Lecture Summary
Objectives
The objectives of this lecture are to familiarize students with various neurotransmitters and their role in modulating behaviors, the classification of neurotransmitters including monoamines (catecholamines and indoleamines), acetylcholine, amino acids, and peptides, the role of neurotransmitters in behavioral modulation and aberrations, the classification of psychopharmacological substances, behavioral correlates and treatment, and the mechanisms of synaptic transmission.
Major Neurotransmitters: Dopamine
Dopamine (DA) is a major catecholaminergic neurotransmitter discovered by Udenfriend in 1964. It is the first step in the synthesis chain of the Adrenergic (also known as Epinephrine) and Noradrenergic (also known as Norepinephrine) neurotransmitter systems. Dopamine was the last to be given the status of a neurotransmitter because it was initially thought to be only an intermediary step in the synthesis of Norepinephrine. Dopamine has a major influence on behavior, especially motor behavior and schizophrenia. These chemicals are also found in the body in the adrenal glands and are used in sympathetic action during emotional states; however, whatever is produced in the body cannot cross the blood-brain barrier to enter the brain. The brain manufactures all the chemicals it needs from precursors (the first compound in the chain), which are taken from the blood circulation.
DA has two types of receptors in the brain: D1 and D2.
π Definition β D1 receptors: These are linked to the stimulation of adenylate cyclase. They are present in the Corpus Striatum, and the Butrypheneones (a class of drugs known as neuroleptics or antipsychotics) are weak antagonists for these receptors.
π Definition β D2 receptors: These are linked to the inhibition of adenylate cyclase. They are present in the pituitary and the Corpus striatum. The Butrypheneones are potent antagonists for these receptors.
DA Pathways
There are three major pathways of the dopamine system:
-
The Nigrostriatal DA system: This is the largest and longest bundle of fibers of neurons containing DA. This major tract has 80% of the brain's dopamine. It originates in the Zona Compacta of the Substantia Nigra and sends projections to the Corpus Striatum. The degeneration of this system leads to Parkinson's disease (a major motor disorder where voluntary movements become increasingly difficult and only stereotypic movements are seen). This system is also involved in schizophrenia. Reduced levels of DA in this system lead to Parkinson's disease, and increased levels lead to schizophrenic symptoms.
-
Mesolimbic system: This is a medially located diffuse (widespread projections) system. It sends nerve fibers to forebrain areas such as the frontal cortical area, the cingulated cortex, the amygdala, and the septum. As the name implies, it is involved with the limbic system (emotional system). Antipsychotic drugs act here to reduce the apathy and lack of affect (emotional content) characteristic of schizophrenia.
-
Tuberoinfundibular system: This is also known as the hypothalamic-hypophyseal connection. It originates from arcuate and periventricular regions of the hypothalamus, with very short fibers ending in the intermediate lobe of the pituitary. This system appears to play a role in hormonal controls and modulations.
Synthesis Pathway
As a rule, the brain manufactures its own neurochemicals including dopamine from the precursor taken in from the blood supply.
Step 1: Phenylalanine is taken in from food and is immediately hydroxylated (adding a hydroxyl molecule) by the enzyme phenylalanine hydroxylase to convert to tyrosine.
Step 2: Tyrosine is then immediately hydroxylated by tyrosine hydroxylase. This is known as the rate limiting step and is sensitive to pharmacological manipulations. This hydroxylation leads to the formation of DOPA.
Step 3: DOPA is similar to the drug L-Dopa, which is effective in treating Parkinson's disease. DOPA is then decarboxylated (removal of the carboxyl molecule) by the enzyme dopa decarboxylase to form Dopamine.
Step 4: Metabolic degradation: a) Dopamine is metabolized by Monoamine Oxidase (MAO), which converts monoamines to aldehydes to make them inactive. MAO is not specific for dopamine but acts on all monoamines (NE, E, and serotonin). It is found in the presynaptic region. b) COMT (catechol O-methyl transferase) acts to transfer the methyl from the catechol molecule to deactivate it. It is found in the synaptic cleft as well as the presynaptic areas.
π Formula: Synthesis Pathway β Phenylalanine β (by phenylalanine hydroxylase) β Tyrosine β (by tyrosine hydroxylase, rate limiting step) β DOPA β (by dopa decarboxylase) β Dopamine
π Example: The drug L-Dopa is effective in treating Parkinson's disease because it provides DOPA, which can then be converted to dopamine in the brain, compensating for the reduced dopamine levels characteristic of the disorder.
Pharmacological Interventions: Steps Where DA Synthesis Pathway Can Be Blocked or Altered
Pharmaceutical substances or drugs act in the central nervous system through the neurochemical systems.
π Definition β Agonists: Drugs that copy/mimic the action of the neurotransmitter or have a similar effect as the NT, or have an excitatory effect on the NT systems.
π Definition β Antagonists: Drugs that block, inhibit, or in any way oppose the action of the NT.
Drugs or exogenously administered substances can affect the NT pathway at various levels: a) They can act directly on neurons containing the NT b) They can act on various points of the synthesis pathway at the pre- or post-receptor site c) They can act on the inactivating enzymes in the cleft or within the presynaptic area
Steps where drugs can interact in the synthesis pathway:
Step 1: The conversion of phenylalanine to tyrosine can be blocked, as in the genetic disorder PKU (phenylketonuria), where phenylalanine builds up and transforms into toxins that damage brain cells. PKU blocks the transport of both tyrosine and tryptophan into the brain.
Step 2: The hydroxylation of tyrosine can be blocked by A-Methyl Para Tyrosine (AMPT), which methylates the tyrosine instead of hydroxylating it. This reduces the level of tyrosine available, leading to reduced dopamine, norepinephrine, and epinephrine. AMPT is effective in reducing catecholamine levels in the brain.
Step 3: The conversion of DOPA into dopamine by dopa decarboxylase can be blocked by a false enzyme A-methyl dopa. This enzyme competes for DOPA and uses it so it cannot be converted into the correct form to become dopamine.
Step 4: Storage vesicles are packed with dopamine. Reserpine, a drug manufactured from Rauwolfia Alkaloids classified as a major and long-lasting tranquilizer, ruptures all vesicles irreversibly and spills the contents into the presynaptic area. These vesicles cannot be repaired until new vesicles are manufactured. Another drug, Tetrabenazine, also opens vesicles and blocks reuptake of DA into the vesicles, but this is not irreversible.
Step 5: The release of the NT from the presynaptic ending and the reuptake back from the synaptic cleft can be blocked. Amphetamine (a stimulant) releases and blocks the reuptake of DA for a prolonged agonistic action. Similarly, Cocaine (another stimulant and street drug) and the Tricyclic group of antidepressants also block reuptake of DA and NE.
Step 6: The deactivation process can be blocked by drugs that block the action of MAO. The drug Pargyline, an MAOI, can increase the amount of DA available by blocking the deaminating process.
Step 7: The post-receptor site can also be blocked or stimulated. Apomorphine is a DA receptor stimulant at pre- and post-receptor sites, increasing levels of DA available for action. Haloperidol, a potent antipsychotic drug, is a DA blocking agent.
π‘ Why this matters: Understanding these specific intervention points explains how different classes of drugs (antipsychotics, stimulants, antidepressants) produce their therapeutic and side effects by targeting distinct steps in neurotransmitter synthesis and transmission.
DA and Behaviors
Dopamine and Motor Activities:
The SN (Substantia Nigra) and Corpus Striatum: The Dopaminergic Nigrostriatal system is atypical in that SN fibers do not cross over to the contralateral hemispheresβthey remain on the same side of the brain. This system innervates the extrapyramidal structures (the basal ganglia), which control motor behavior at the subcortical level.
A) Damage to SN leads to Parkinson's disease. The dopaminergic neurons in the Substantia Nigra have dark pigmentation; a pale SN indicates damage to the DA neurons. Reduced levels of DA in SN lead to Parkinson's symptoms. If we increase levels of dopamine by injecting Dopa (or L-Dopa) into the SN, we see a reduction in Parkinson's symptoms.
B) Evidence shows that rats injected with 6-OHDA (a toxic agent that selectively damages only DA pathways and neurons by retrograde transmission) exhibit the same symptoms as in Parkinson's (rigidity, tremor, etc.). This indicates that DA is involved in Parkinson's as well as motor behavior.
C) If DA levels are increased in animals or humans by injections of L-Dopa, it leads to stereotypic (repetitive) motor behavior. Stereotypic behavior is a symptom of higher than normal levels of DA in the brain. Apomorphine and Amphetamine (both strong agonists of DA) at high enough doses lead to stereotypic behaviors.
D) Injections of Haloperidol and Chlorpromazine (antipsychotic drugs that block DA activity) block the stereotypy induced by amphetamine injections.
π Example: Increase DA by amphetamine β Stereotypy. Block DA by Haloperidol β Reduce amphetamine-induced stereotypy.
E) Unilateral lesions of 6-OHDA lead to asymmetry in body posturesβthe body becomes lopsided. The body turns from the side with high DA to the side with low DA. This lopsided body posture is exaggerated by amphetamine and apomorphine (Ungerstedt et al., Najam 1980). Body postural asymmetry is from the side with more DA to the side with lesser DA.
F) Bilateral lesions with 6-OHDA lead to complete reduction of DA in the brain. Animals with bilateral lesions do not eat (aphagia), drink (adipsia), and cannot survive. They recover feeding only if force-fed.
Dopamine and Depression:
- Antidepressants such as Monoamine oxidase inhibitors (MAOI) and the Tricyclics both increase levels of DA.
- Alpha methyl para tyrosine (AMPT) if injected reduces both NA and DA levels in the brain. If we then inject MAOI, there is reduced effectiveness of the antidepressant effect of MAOI. However, evidence indicates that these have greater interaction with NA than DA (e.g., Desipramine has no effect on DA neurons).
Dopamine and Hyperactivity: Hyperactivity is due to increased levels of dopamine in the brain. This is also seen with injections of Amphetamine and Apomorphine. The market drug "speed" is actually amphetamine, which users take to feel tireless with increased energy and euphoria.
Dopamine and Schizophrenia: There is strong evidence that DA is involved in schizophrenia:
- Drugs effective in treating schizophrenic symptoms are strong DA blockers. The more effective the drug is as a DA blocker, the greater its antipsychotic potency/efficacy.
- The greater the efficacy of treatment (reducing DA), the greater the side effect of extrapyramidal symptoms (Parkinson's-like tremor, rigidity). These appear because DA is decreased postsynaptically. The DA synapses are blocked by antipsychotic drugs such as Phenothiazines (largectil and haloperidol: haldol).
- Patients with Parkinson's when treated with L-Dopa start exhibiting symptoms of schizophrenia as a side effect.
- Chronic users of amphetamine end up with symptoms of paranoid schizophrenia.
π‘ Why this matters: Dopamine's involvement in such diverse behaviorsβfrom motor control to mood regulation to psychosisβexplains why drugs targeting the dopamine system can have both therapeutic effects (reducing schizophrenic symptoms) and significant side effects (inducing Parkinson's-like symptoms).
β Key Takeaways
Dopamine is synthesized from phenylalanine through a four-step pathway (phenylalanine β tyrosine β DOPA β dopamine), with the hydroxylation of tyrosine by tyrosine hydroxylase being the rate-limiting step. The three major dopaminergic pathwaysβnigrostriatal, mesolimbic, and tuberoinfundibularβare responsible for motor control, emotional processing, and hormonal regulation respectively. Pharmacological agents can interact at each step of dopamine synthesis and transmission, with agonists like amphetamine increasing dopamine activity and antagonists like haloperidol blocking it. Dopamine is critically involved in motor behavior (Parkinson's disease results from reduced DA, while stereotypic behavior results from increased DA), depression (antidepressants increase DA levels), hyperactivity, and schizophrenia (antipsychotics are DA blockers; the more potent the DA blockade, the greater the antipsychotic efficacy). Understanding the specific points of pharmacological intervention in the dopamine pathway is essential for comprehending both therapeutic drug actions and their side effects.
π§ Quick Revision Questions
- What are the four steps in the dopamine synthesis pathway, and which step is considered the rate-limiting step?
- Name the three major dopaminergic pathways in the brain and describe the function or behavioral correlate of each.
- At which step of the dopamine synthesis pathway does reserpine act, and what is the effect of this drug?
- What is the relationship between dopamine levels and Parkinsons disease, and how does L-Dopa treatment relate to schizophrenic symptoms?
- Explain how amphetamine acts on the dopamine system and what behavioral effects result from its agonistic action.
π Lecture 33 β Basic Neurochemistry
π Overview: This lecture examines norepinephrine/noradrenaline (NA), a major catecholamine neurotransmitter involved in mood, arousal, reward, and stress responses. It covers NA synthesis, pathways, receptors, and how various psychotropic drugs modulate NA function at each step of neurotransmission, linking NA to specific behaviors like arousal and conditioned avoidance.
ποΈ Topics Covered
The lecture begins by introducing norepinephrine/noradrenaline as a catecholamine neurotransmitter synthesized from dopamine, then details its synthesis via dopamine B-hydroxylase, deactivation pathways producing VMA and MHPG metabolites, and the two major noradrenergic pathways (dorsal and ventral bundles originating in the pons and medulla). It describes alpha and beta receptor subtypes with their locations and functions, then systematically explains seven steps where drugs can modify NA synthesis and action (from enzyme inhibition to reuptake blockade). Finally, it covers NAβs role in behavioral arousal and conditioned avoidance learning.
π Lecture Summary
Basic Neurochemistry β Lesson 33 Objectives
This lesson aims to familiarize students with various neurotransmitters (NTs) and their role in modulating behaviors, the classification of NTs (monoamines such as catecholamines and indoleamines, acetylcholine, amino acids, and peptides), the role of NTs in behavioral modulation and aberration, drugs and behavior, classification of psychopharmacological substances, behavioral correlates and treatment, and the mechanism of synaptic transmission.
Major Neurotransmitter: Catecholamines β Norepinephrine/Noradrenaline
Norepinephrine (NE), also known as Noradrenaline (NA), is one of the major NTs of the brain, falling under the general category of monoamines and further categorized as a catecholamine because of its chemical composition. Synapses using NA are known as noradrenergic synapses. NA is found in various parts of the brain (hypothalamus, midbrain), the autonomic nervous system (important role in sympathetic functions and hormonal release for fight or flight), and the adrenal glands. NA is involved in a large number of behaviors with wider influence than dopamine (DA), including mood, emotional states, motivation (hunger, thirst, fight/flight), dream, rewards (learning), sleep, alertness, and wakefulness.
NA originates from a small group of neurons in the back part of the brain and projects via fibers and axons to widespread brain regions, explaining its involvement in many behaviors.
- Noradrenergic synapses lead to Inhibitory Post Synaptic Potentials (IPSPs) in the CNS and Excitatory Post Synaptic Potentials (EPSPs) in the Autonomic Nervous System (including the sympathetic nervous system) and target organs such as the heart.
- Noradrenergic neurons release NA through axonal varicosities (beadlike swellings of axonal branches) rather than from terminal buttons. Varicosities give NA axonal branches the appearance of beaded chains.
- NA is synthesized in the adrenal medulla and the brain from DA. The brain manufactures all NTs independently, including NA. Large amounts of NA cannot cross the blood-brain barrier to enter the brain.
π Definition β Axonal varicosities: Beadlike swellings of axonal branches from which NA is released (instead of terminal buttons).
π Definition β Noradrenergic synapses: Synapses that use norepinephrine/noradrenaline as their neurotransmitter.
NA Synthesis
- Synthesis: A simple one-step process transforms DA into NA. DA is hydroxylated by Dopamine B-hydroxylase (discovered in 1960 in the adrenal medulla). Synthesis from DA to NE takes place within the vesicles (unlike other NTs where synthesis occurs in the cell body).
- The hydroxylation process can be blocked by Disulfiram, leading to a buildup of DA while reducing NE levels.
- Deactivating Norepinephrine by MAO (monoamine oxidase) and COMT (catechol-O-methyltransferase) leads to: a) Vanylmandellic Acid (VMA) β a metabolite found mostly in the body (very little in the brain as it is excreted quickly). b) MHPG (3-methoxy-4 hydroxyphenylglycol) β a glycol derivative; under stress, MHPG amounts increase in the locus coeruleus.
π Formula: DA + Dopamine B-hydroxylase β NA (hydroxylation within vesicles) π Formula: NA + MAO/COMT β VMA + MHPG (deactivation metabolites)
Noradrenergic Pathways
There are two major NA pathways β the Dorsal bundle and the Ventral bundle with several projecting pathways (A1, A2, A4, A5, A6, A7). All originate in lower brain areas (pons and medulla) and ascend to the cortex, limbic system, and hypothalamus.
- A6 (Dorsal bundle): Originates in the locus coeruleus (located on the ventral areas of the ventricles) and sends diffuse innervations to the cerebellum, cerebral cortex, and hippocampus through the Medial Forebrain Bundle (MFB). Involved in sleep, awakening, moods, neuro-endocrine functions, and temperature regulation.
- A1, A2, A4, A5, A7 (Ventral bundle): Originate in the pons and medulla, innervating the brainstem and hypothalamus. Ascending fibers of A5 and A7 project to the cortex, hypothalamus, and parts of the limbic system (hippocampus and septum), while descending fibers go down into the spinal cord.
π Definition β Locus coeruleus: A nucleus in the pons where the dorsal NA bundle originates; involved in sleep, arousal, and stress responses.
Receptors
There are two types of NA receptors identified by their sensitivities to various drugs: Alpha receptors and Beta receptors.
- Alpha1 and Beta1: Found mainly in post-receptor membranes.
- Alpha2: Primarily presynaptic autoreceptors (emerge from the presynaptic membrane area to monitor and control NT levels by self-inhibiting action).
- Beta2 receptors: Found in the CNS, associated with glia cells, muscles, and blood vessel walls.
Receptor Details:
- A1: Located post-synaptically on blood vessels, spleen, and peripheral tissues. Prazosin and Indoramin are selective antagonists working near the heart. These receptors carry brain commands directly to organs.
- A2: Located on presynaptic nerve terminals in the periphery (not in the brain). Yohimbine is a selective antagonist; Clonidine is a selective agonist. Also located in the pancreas.
- B1: Linked to stimulation of adenylate cyclase. Found in greater numbers in the heart and cerebral cortex. Epinephrine and NE are potent agonists. Presence varies across brain regions.
- B2: Linked to stimulation of adenylate cyclase. Found in high concentration in the lungs and cerebellum. Epinephrine (E) is more potent than NE at these receptors. Salbutamol is a selective agonist.
π Definition β Autoreceptor: A receptor located on the presynaptic neuron that monitors and controls NT levels through self-inhibiting action (e.g., Alpha2 receptors for NA).
Steps in NA Synthesis Where Drugs Can Modulate Action
Step 1: Enzyme Synthesis
- a) Alpha Methyl Para Tyrosine (AMPT) blocks the hydroxylation of tyrosine by tyrosine hydroxylase (the rate-limiting step for both DA and NA). Reducing available tyrosine reduces both DA and NA.
- b) Disulfiram and FLA-63 block Dopamine B-hydroxylase action on dopamine, allowing DA buildup but preventing conversion to NA.
Step 2: Storage Vesicles
- Reserpine: Long-lasting, irreversible damage to storage vesicles (effect on NA is long-lasting).
- Tetrabenazine: Interferes with storage vesicles but effect is neither long-lasting nor irreversible.
Step 3: Release
- Amphetamine: Increases the release of NA molecules from the presynaptic area and also blocks reuptake for enhanced and long-lasting effects.
Step 4: Post-receptor Site Interaction
- Clonidine: Very potent receptor stimulant (agonist).
- Phentolamine: An A-blocking agent (antagonist).
- Sotalol: A B-blocking agent (antagonist).
Step 5: Reuptake
- Desipramine (tricyclic antidepressant): Blocks reuptake of NA molecules, enhancing NA levels in the synaptic cleft.
Step 6: Degradation by MAO
- MAO inhibitors (e.g., Pargylin): Block MAO action, leading to increased NA levels.
Step 7: Degradation by COMT
- Tropolamine: Blocks COMT action in the synaptic cleft.
π Definition β Psychotropic drugs: Drugs that act on psychological states, modifying neurotransmitter function at various steps of synthesis, storage, release, receptor interaction, reuptake, and degradation.
NA and Behaviors
Arousal: Behavioral arousal and electrical arousal in the brain are correlated with increases in NE via MAOI (monoamine oxidase inhibition). Increased available NA leads to increased arousal seen in behavioral excitation and EEG activity. In states of stress, NA levels increase; stressed individuals who cannot sleep show increased brain NA levels. This is clearly NA involvement (no DA involvement β complete depletion of striatal DA still leads to waking and sleeplessness). Injecting NA intraventrically (directly into the brain) also leads to behavioral excitation. Increases in NA produce arousal, excitation, and increased activity.
NA and Conditioned Avoidance: NA is involved in conditioned avoidance in learning and conditioning paradigms. Injecting Reserpine (ruptures vesicles to spill NA) and Alpha Methyl Paratyrosine (blocks further tyrosine/DA/NA synthesis) results in complete abolishment of a learned conditioned avoidance response to electric shock. This shows NAβs role in avoidance behavior, possibly through reward/punishment mechanisms or learning/memory centers.
To confirm only NA decreases lead to this response: giving Disulfiram or FLA-63 (which increase DA but decrease NE by blocking NE synthesis) also abolishes the learned avoidance response.
π Definition β Conditioned avoidance: A learned response to avoid an aversive stimulus (e.g., electric shock) that depends on intact NA function.
β Key Takeaways
Norepinephrine/noradrenaline is a catecholamine neurotransmitter synthesized from dopamine via dopamine B-hydroxylase within vesicles, with deactivation by MAO and COMT producing VMA and MHPG metabolites. NA originates from the locus coeruleus (dorsal bundle) and medulla/pons (ventral bundle), projecting to widespread brain regions via axonal varicosities. NA receptors include alpha (Ξ±1 post-synaptic, Ξ±2 presynaptic autoreceptors) and beta (Ξ²1 and Ξ²2, linked to adenylate cyclase) subtypes with distinct locations and drug sensitivities. Psychotropic drugs modulate NA function at seven stepsβenzyme synthesis (AMPT, Disulfiram), storage vesicles (Reserpine), release (Amphetamine), receptor interaction (Clonidine, Phentolamine, Sotalol), reuptake (Desipramine), MAO degradation (Pargylin), and COMT degradation (Tropolamine). Behaviorally, NA is essential for arousal (increased NA causes excitation and wakefulness independent of DA) and conditioned avoidance learning (decreased NA abolishes learned avoidance responses).
π§ Quick Revision Questions
- What enzyme converts dopamine into norepinephrine, and where within the neuron does this conversion take place?
- Name the two major noradrenergic pathways and the primary nucleus of origin for the dorsal bundle.
- What are the two main categories of NA receptors, and which subtype functions as a presynaptic autoreceptor?
- Which drug blocks NA reuptake and belongs to the tricyclic antidepressant group, and what effect does it have on synaptic NA levels?
- How does decreasing NA (without decreasing DA) using Disulfiram or FLA-63 affect learned conditioned avoidance behavior?
π Lecture 34 β Basic Neurochemistry
π Overview: This lecture continues the exploration of norepinephrine (NE) and its role in stress, feeding, self-stimulation, and depression. It then introduces serotonin (5-HT) as a major indolamine neurotransmitter, covering its synthesis, anatomical pathways, and how drugs interact at each step of serotonin transmission to modulate behavior and treat psychopathology.
ποΈ Topics Covered
This lecture begins by examining NEβs involvement in stress responses, feeding behavior regulation via the lateral hypothalamus and ventromedial hypothalamus, intracranial self-stimulation (reward), and the catecholamine hypothesis of depression. It then introduces serotonin (5-hydroxytryptamine, 5-HT) as an indolamine neurotransmitter, detailing its historical discovery, synthesis from tryptophan, storage, deactivation, and the anatomical locations of serotonergic pathways (raphe nuclei). Finally, it explains how drugs (PCPA, Reserpine, LSD, Tricyclics, MAOIs) can modulate serotonin at each step of synthesis, storage, release, receptor interaction, reuptake, and degradation.
π Lecture Summary
NE and Behaviors (continued)
Stress: Stress can be induced in the laboratory by giving continuous, inescapable foot shocks to rats. Stress induced by foot shocks leads to increased NA (norepinephrine) levels and turnover in the hindbrain. Increased turnover rates mean more NA is being used and metabolized. Trauma of all kinds also increases NA activity in the brain. Similarly, Electroconvulsive therapy (ECT) leads to increased NA levels in the forebrain.
NA and Feeding: The NA system is involved in the control of feeding behaviors. If NA is administered directly into the Lateral Hypothalamus (LH), it leads to increased eating in animals that have already eaten to the point of satiation. This effect is specific to NA: injecting phentolamine (an Ξ±-adrenergic blocker) blocks NA-induced feeding. π‘ Why this matters: Liebowitz (1971) demonstrated that NA may act to reduce the inhibition of the LH feeding center by the Ventromedial Hypothalamus (VMH). The LH starts feeding, and the VMH stops it by telling the LH to stop sending signals. When NA is injected, it stops the inhibition from the VMH, allowing feeding messages to continue.
π Definition β Phentolamine: An Ξ±-adrenergic blocker that blocks NA-induced feeding.
NA and Self-Stimulation (ICS): Positive reinforcement or βrewardβ is linked to NA. Intracranial Self-Stimulation (ICS) areas in the brain correspond closely to the distributions of NA and DA systems. If alpha-methyl-paratyrosine (AMPT) is injected, it reduces tyrosine, DA, and NA, and also blocks the self-stimulation response. To determine which neurotransmitter is involved, researchers used drugs that block only DA, only NA, or only 5-HT one by one after AMPT. The AMPT blockade is reversed by Ξ±-receptor agonists of NA, not by Ξ²-receptor agonists, DA agonists, or 5-HT agonists, showing that NA is involved. Using push-pull cannulae in the ventricle, researchers reported that self-stimulation leads to an increase in the release of NA. The NA Dorsal bundle is more involved than the ventral bundle.
NA and Depression: The effectiveness of Monoamine Oxidase Inhibitors (MAOIs) in treating depression supports the Catecholamine Hypothesis of Depression, particularly the involvement of NA. Long-term antidepressant treatment in animals leads to a reduction in NA-stimulated cyclic AMP (involving beta receptors). This indicates that more NE stays available, so less needs to be released. Antidepressants increase the synaptic availability of NE. Reserpine (which destroys storage vesicles and depletes NE, DA, and 5-HT from presynaptic membranes) leads to a depression-like syndrome. Iproniazid (an MAOI and effective antidepressant) increases brain concentrations of NE and 5-HT.
Major Neurotransmitters: Monoamines: Indolamines
Serotonin: Indolamine (5-Hydroxytryptamine or 5-HT) Serotonin is a major neurotransmitter with an important role in several behaviors, from sleep to depression. Scientists knew since the mid-19th century that a substance caused powerful contraction of smooth muscles. In American labs, it was called serotonin; Italian scientists called it enteramine. These substances were eventually found to be identical to 5-Hydroxytryptamine (5-HT). It has a strong resemblance to the LSD molecule.
The precursor for 5-HT is tryptophan, which varies with daily intake of tryptophan-rich foods (milk, red meat, bananas, pineapples). About 90% of 5-HT is found in the gastrointestinal area, and only about 1-2% in the brain. The highest concentration of 5-HT in the brain is found in the pineal gland (a small organ on the dorsal surface of the thalamus). The pineal contains about 50% more serotonin per gram of brain than other brain areas. The extension of pineal serotonin is melatonin, which is enhanced by light and suppressed by darkness, bringing daily and seasonal changes in 5-HT content.
Serotonin Synthesis:
- Tryptophan: This is the first step. Tryptophan enters the cells in competition with phenylalanine.
- Hydroxylation of Tryptophan: This is the rate-limiting step. The hydroxylation of tryptophan at the 5th position forms 5-Hydroxytryptophan (5-HTP). The enzyme involved is Tryptophan Hydroxylase. This step can be blocked by the drug Parachlorophenylalanine (PCPA). One injection of PCPA (200 mg/kg) in rats depletes brain 5-HT drastically (to about 20%), and recovery can take weeks.
- Decarboxylation: 5-HTP is immediately decarboxylated to form 5-HT. The enzyme L-Amino Acid Decarboxylase is involved (the same enzyme used for catecholamines).
- Deactivation: Serotonin is deaminated by Monoamine Oxidase (MAO). The metabolite formed is 5-Hydroxy Indole Acetic Acid (5-HIAA).
π Definition β Parachlorophenylalanine (PCPA): A drug that competes with tryptophan for tryptophan hydroxylase and binds irreversibly, depleting brain 5-HT. π Formula (Pathway): Tryptophan β [Tryptophan Hydroxylase] β 5-HTP β [L-Amino Acid Decarboxylase] β 5-HT β [MAO] β 5-HIAA
Serotonergic Anatomical Location and Pathways
Dahlstrom and Fuxe (1964) identified about nine clusters of 5-HT neurons in the nuclei of the raphe system, located in the midline of the pons and upper brain stem. Ascending 5-HT bundles travel through the Medial Forebrain Bundle (MFB) with terminals in the reticular formation, hypothalamus, lateral geniculate nuclei, preoptic area, hippocampus, and cortex (crucial for sleeping and awakening). These also project into the telencephalon, diencephalon, and descend into the spinal cord.
Pathways:
- Nuclei Raphe Dorsalis (B7 receptors): Projects to the neocortex, olfactory bulb, thalamus, amygdala, hippocampus, substantia nigra, and locus coeruleus.
- Nuclei Centralis Superior (B8 receptors): Projects to the cerebral cortex, hippocampus, superchiasmatic nuclei (SCN), anterior hypothalamus, medial preoptic area, and the raphe dorsalis.
- Nuclei Raphe Magnus (B3 receptors): Extends to the medulla and anterior hypothalamic area.
- Nuclei Raphe Obscurus (B2 receptors): The powerful hallucinogen LSD acts here.
- Raphe Pallidus (B1 receptors): Contains substance P (a peptide involved in pain) and goes down into the spinal cord.
Steps in 5HT Synthesis Where Drugs Can Modulate Action
Step 1: Synthesis: Tryptophan is converted to 5-HTP by tryptophan hydroxylase. This can be blocked by PCPA.
Step 2: Storage: Reserpine damages storage vesicles for DA, NE, and 5-HT. When reserpine is administered along with 5-HTP or DOPA, there is increased sedation. Injections of PCPA (removing 90% of brain serotonin) before reserpine prevented the behavioral effects of reserpine.
Step 3: Release: There are no specific serotonin blocking agents, but LSD potentiates serotonin effects in low doses. LSD inhibits the release of serotonin by blocking the firing of serotonergic neurons. In high doses, LSD increases 5-HT levels by reducing breakdown. LSD appears to decrease the release of 5-HT.
Step 4: Receptor Interaction: LSD acts as a partial agonist at the receptor sites of the post-synaptic membrane.
Step 5: Reuptake: Serotonin action can be terminated by reuptake. Tricyclics (like Imipramine) increase 5-HT levels by inhibiting reuptake. Selective Serotonin Reuptake Inhibitors (SSRIs) are effective for treating anxiety.
Step 6: Degradation: Degradation by MAO can be inhibited by MAOIs. Iproniazid blocks MAO action in the presynaptic area.
β Key Takeaways
- Norepinephrine is critically involved in stress, feeding (via the LH/VMH circuit), reward (self-stimulation), and depression, as supported by the catecholamine hypothesis and drug effects (Reserpine, MAOIs).
- Serotonin (5-HT) is an indolamine synthesized from tryptophan via the rate-limiting enzyme tryptophan hydroxylase, which is blocked by PCPA, and is deactivated into 5-HIAA by MAO.
- The serotonergic system originates from the raphe nuclei and projects widely through the MFB to the forebrain, cortex, and spinal cord, modulating sleep, mood, and pain.
- Drugs modulate serotonin at every step: PCPA blocks synthesis, Reserpine blocks storage, LSD affects release and receptors, Tricyclics/SSRIs block reuptake, and MAOIs block degradation.
- Understanding these systems and drug interactions is fundamental to explaining the mechanisms of action for antidepressants, antipsychotics, and hallucinogens.
π§ Quick Revision Questions
- What is the specific role of the Ξ±-adrenergic blocker phentolamine in the experiment on NA-induced feeding?
- What is the evidence from the self-stimulation paradigm that points to NA (and not DA) as the main neurotransmitter for reward?
- What is the rate-limiting step in serotonin synthesis, and which drug irreversibly inhibits it?
- Name the specific raphe nucleus (and its receptor type, B2) where the hallucinogen LSD acts.
- How does Reserpine affect serotonin levels, and what experimental result showed that serotonin depletion accounts for Reserpineβs behavioral effects?